Keliomics logo — Engineering Clinically Benchmarked -ex vivo- Breast Tumors i...

Keliomics

Engineering Clinically Benchmarked -ex vivo- Breast Tumors in Human Breast Tissue

Founded 2022 United States Portland, United States 14 employees Biotechnology, Health Care

General Information

Company Name Keliomics
Founded Year 2022
Location United States Portland, United States
Employees 14
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with Keliomics. To contact Keliomics, visit keliomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Keliomics compare?

A PDF of Keliomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Keliomics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Keliomics

Keliomics is a groundbreaking startup specializing in Biotechnology and Health Care, founded in 2022. With the slogan "Engineering Clinically Benchmarked -ex vivo- Breast Tumors in Human Breast Tissue," Keliomics offers a paradigm-shifting technology that revolutionizes cancer treatment by keeping human tissues and tumors alive outside the human body. Despite the absence of specific information regarding its headquarters, Keliomics is a promising venture poised to make a significant impact in the field of biotechnology and healthcare. As of now, there is no record of their last investment or the associated investors. Keliomics' innovative approach and focus on improving cancer treatment make it a compelling prospect for potential venture capital investment.

Business keywords: Precision Medicine, Oncology Research, Cancer Treatment Innovation, Microphysiological Systems, Tumor Analysis, Ex Vivo Technology, Biomedical Engineering, Human Tissue Research, Innovative Healthcare Solutions

No funding data available for Keliomics yet.

Keliomics Alternatives & Competitors

View All Alternatives
Keliomics vs

Innovation ★ Tissue Engineering ★ Cell Therapy ★ Impact

47 employees
Biotechnology, Health Care
Keliomics vs

Improving patient outcomes through innovations in biological therapeutics

Seed
4 employees
Biotechnology, Health Care
Keliomics vs

A precision oncology company focused on the treatment and prevention of virus-associated cancers tha...

IPO
31 employees
Biopharma, Biotechnology

FAQ About Keliomics

Engineering Clinically Benchmarked -ex vivo- Breast Tumors in Human Breast Tissue
Keliomics was founded in 2022.
Keliomics is headquartered in Portland, United States.
Keliomics operates in Biotechnology and Health Care. Its work centres on Precision Medicine, Oncology Research, Cancer Treatment Innovation and Microphysiological Systems.
Keliomics has approximately 14 employees.
Top alternatives and competitors to Keliomics include Bonus Biogroup, ImmunoBiochem Corporation, Viracta Therapeutics, Inc., GILUPI GmbH, Genus Oncology LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Keliomics and Bonus Biogroup are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Keliomics, https://bouncewatch.com/company/keliomics, updated 8 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes